MedTrace Logo

Angiotensin II vs. Vasopressin in Septic Shock

NCT05193370 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2024-03-15

No results posted yet for this study

Summary

This will be a randomized controlled unblinded pragmatic single-center pilot trial of the use of vasopressin vs. angiotensin II as a second-line vasopressor in patients with septic shock and persistent hypotension despite moderate-to-high doses of norepinephrine.

Conditions

  • Septic Shock

Interventions

DRUG

Angiotensin II

Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring hormone of the same name, peptide hormone of the renin-angiotensin-aldosterone system (RAAS), that was FDA-approved in 2017 as a vasoconstrictive agent in the treatment of vasodilatory shock.

DRUG

Vasopressin

Vasopressin (Vasostrict) is a pharmacologic version of a naturally occurring peptide hormone that serves as a vasoconstrictive agent in the treatment of vasodilatory shock.

Sponsors & Collaborators

  • La Jolla Pharmaceutical Company

    collaborator INDUSTRY

  • National Center for Advancing Translational Sciences (NCATS)

    collaborator NIH

  • University of New Mexico

    lead OTHER

Principal Investigators

  • Joao P Teixeira, MD · University of New Mexico School of Medicine

  • Nathan D Nielsen, MD MSc · University of New Mexico School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-03
Primary Completion
2022-11-30
Completion
2022-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05193370 on ClinicalTrials.gov